Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] +/- Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage +/- Darbepoetin Alfa in Patients With Primary Breast Cancer.

Next Previous
X
Search
Trial Profile

Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] +/- Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage +/- Darbepoetin Alfa in Patients With Primary Breast Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Methotrexate; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PREPARE

    • Most Recent Events

    • 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2011 Results published in the Annals of Oncology.
    • 30 May 2008 Interim results reported at ASCO 2008

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top